Insulin resistance often develops gradually, long before diabetes is formally diagnosed
Make sure your receipts, prescription, and LMN (if required) all match the documented diagnosis
These eligibility criteria are similar to those used for Semaglutide and reflect FDA-approved indications for obesity treatment
In many cases, a patient will experience recurrent or ongoing periods of chronic back pain that can prevent them from working or participating in an active, healthy lifestyle
Options include: brand-name Wegovy or Zepbound (covered by some insurance plans), the new Medicare GLP-1 Bridge ($50/month for eligible Medicare beneficiaries starting July 2026), Foundayo (orforglipron, $149/month oral pill), manufacturer patient assistance programs, or transitioning to a 503A compounding pharmacy if a documented clinical need exists (such as an allergy to an inactive ingredient)